QUIT — Achieve Life Sciences Share News
0.000.00%
Last trade - 00:00- $746.03m
- $573.64m
Achieve Life Sciences Inc expected to post a loss of 36 cents a share - Earnings Preview
Achieve Life Sciences Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Achieve Life Sciences Says Cytisinicline NDA Submission To FDA Planned For June 2025
Achieve Life Sciences Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Achieve Life Sciences reports wider-than-expected fourth-quarter net loss
Achieve Life Sciences Inc expected to post a loss of 32 cents a share - Earnings Preview
Achieve Life Sciences Inc reports results for the quarter ended September 30 - Earnings Summary
Achieve Life Sciences Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Achieve Life Sciences President And Cmo, Dr. Cindy Jacobs, Speaks At FDA And Nih Smoking Cessation Public Meeting
Brief: Achieve Life Sciences Promotes Jaime Xinos To Chief Commercial Officer To Advance Commercial Readiness Of Cytisinicline
Brief: Achieve Life Sciences Announces Completion Of Enrollment In ORCA-OL Clinical Trial
Brief: Achieve Life Sciences May Offer, Sell Shares Of Common Stock Of Up To $50.0 Million From Time To Time
Achieve Life Sciences Inc reports results for the quarter ended in June - Earnings Summary
Achieve Life Sciences Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Achieve Life Sciences Files For Mixed Shelf Of Up To $200 Million
Brief: Achieve Life Sciences-In June, Co Entered Into Non-Binding Term Sheet To Refinance Extend Maturity Date Of Term Loans With Silicon Valley Bank, Affiliates
Achieve Life Sciences Inc expected to post a loss of 24 cents a share - Earnings Preview
Health Rounds: Editas gene editing treatment restores sight in inherited blindness
Brief: Achieve Life Sciences Files Prospectus Related To Offer & Sale From Time To Time Of Up To 13.1 Million Shares Of Common Stock